Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-074281
Filing Date
2025-08-11
Accepted
2025-08-11 16:01:07
Documents
79
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0250224-10q_oruka.htm   iXBRL 10-Q 1312278
2 CERTIFICATION ea025022401ex31-1_oruka.htm EX-31.1 11791
3 CERTIFICATION ea025022401ex31-2_oruka.htm EX-31.2 11886
4 CERTIFICATION ea025022401ex32-1_oruka.htm EX-32.1 7559
  Complete submission text file 0001213900-25-074281.txt   7134506

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE orka-20250630.xsd EX-101.SCH 68087
6 XBRL CALCULATION FILE orka-20250630_cal.xml EX-101.CAL 32465
7 XBRL DEFINITION FILE orka-20250630_def.xml EX-101.DEF 334184
8 XBRL LABEL FILE orka-20250630_lab.xml EX-101.LAB 560947
9 XBRL PRESENTATION FILE orka-20250630_pre.xml EX-101.PRE 353863
81 EXTRACTED XBRL INSTANCE DOCUMENT ea0250224-10q_oruka_htm.xml XML 980114
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22873 | Film No.: 251201893
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)